

Resource Summary Report

Generated by [dkNET](#) on Aug 20, 2026

Rat Anti-CD44 Monoclonal Antibody, Allophycocyanin Conjugated, Clone IM7

RRID:AB_398661

Type: Antibody

Proper Citation

BD Biosciences Cat# 559250, RRID:AB_398661

Antibody Information

URL: http://antibodyregistry.org/AB_398661

Proper Citation: BD Biosciences Cat# 559250, RRID:AB_398661

Target Antigen: CD44

Host Organism: rat

Clonality: monoclonal

Comments: Applications: Flow cytometry

Antibody Name: Rat Anti-CD44 Monoclonal Antibody, Allophycocyanin Conjugated, Clone IM7

Description: This monoclonal targets CD44

Target Organism: mouse

Clone ID: IM7

Antibody ID: AB_398661

Vendor: BD Biosciences

Catalog Number: 559250

Record Creation Time: 20250820T064406+0000

Record Last Update: 20250821T004832+0000

Ratings and Alerts

No rating or validation information has been found for Rat Anti-CD44 Monoclonal Antibody, Allophycocyanin Conjugated, Clone IM7.

No alerts have been found for Rat Anti-CD44 Monoclonal Antibody, Allophycocyanin Conjugated, Clone IM7.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 35 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Srinivasan T, et al. (2026) The gut microbiota directs vitamin A flux to regulate intestinal T cell development. Cell host & microbe.

Chen C, et al. (2026) B cells disrupt tertiary lymphoid structure formation and suppress anti-tumor immunity. Cancer cell.

Guleed S, et al. (2026) CD8+ T cell responses recognizing immunodominant Chlamydia antigens fail to protect against infection. iScience, 29(4), 115242.

Pan J, et al. (2026) A senescent tumor cell-derived nanovesicle directly primes splenic T cells to potentiate cancer radiotherapy. Cell reports. Medicine, 7(4), 102709.

Laulhé X, et al. (2026) B cell-intrinsic type I interferon signaling contributes to defective antibody responses to a model antigen during persistent LCMV infection. Cell reports, 45(4), 117145.

Yang Z, et al. (2025) Temporally programmed STING nanoadjuvant delivery unlocks synergistic chemotherapy-induced antitumor immunity. Science advances, 11(29), eadw0797.

Yu H, et al. (2025) UDP-GlcUA triggers PKR kinase activity to promote liquid-liquid phase separation of TOP2A and enhances radioimmunotherapy resistance. Molecular cell, 85(21), 3913.

Verhagen MP, et al. (2024) The SW480 cell line as a model of resident and migrating colon cancer stem cells. iScience, 27(9), 110658.

Gonçalves MP, et al. (2024) A1-reprogrammed mesenchymal stromal cells prime potent antitumoral responses. iScience, 27(3), 109248.

Fukaya T, et al. (2023) Gut dysbiosis promotes the breakdown of oral tolerance mediated through dysfunction of mucosal dendritic cells. Cell reports, 42(5), 112431.

Liu H, et al. (2023) Neutralizing IL-8 potentiates immune checkpoint blockade efficacy for glioma. *Cancer cell*, 41(4), 693.

Du H, et al. (2023) Suppression of TREX1 deficiency-induced cellular senescence and interferonopathies by inhibition of DNA damage response. *iScience*, 26(7), 107090.

Pandey SP, et al. (2022) Tet2 deficiency drives liver microbiome dysbiosis triggering Tc1 cell autoimmune hepatitis. *Cell host & microbe*, 30(7), 1003.

Damasceno LEA, et al. (2022) STING is an intrinsic checkpoint inhibitor that restrains the TH17 cell pathogenic program. *Cell reports*, 39(8), 110838.

Miller CL, et al. (2022) Systemic delivery of a targeted synthetic immunostimulant transforms the immune landscape for effective tumor regression. *Cell chemical biology*, 29(3), 451.

Bikorimana JP, et al. (2022) Promoting antigen escape from dendritic cell endosomes potentiates anti-tumoral immunity. *Cell reports. Medicine*, 3(3), 100534.

Park JY, et al. (2022) In vivo availability of the cytokine IL-7 constrains the survival and homeostasis of peripheral iNKT cells. *Cell reports*, 38(2), 110219.

Agliano F, et al. (2022) Nicotinamide breaks effector CD8 T cell responses by targeting mTOR signaling. *iScience*, 25(3), 103932.

Xu T, et al. (2022) Alternative splicing downstream of EMT enhances phenotypic plasticity and malignant behavior in colon cancer. *eLife*, 11.

Lynn MA, et al. (2022) Protocol to colonize gnotobiotic mice in early life and assess the impact on early life immune programming. *STAR protocols*, 3(4), 101914.